Relmada Therapeutics acquires Sepranolone from Asarina Pharma
Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement ...
GlobalData on MSN3d
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.
FierceBiotech3d
After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
The Pharma Letter3d
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...
Nasdaq4d
Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for Tourette Syndrome Treatment Development
Relmada Therapeutics has announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid developed for treating Tourette syndrome (TS) and related compulsive disorders, from Asarina Pharma ...
Morningstar4d
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled ...
Nasdaq4d
Relmada Therapeutics Acquires Sepranolone From Asarina Pharma For Potential TS Treatment
(RTTNews) - Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company, on Thursday announced the acquisition of Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB.
Investing3d
Relmada Therapeutics Inc (RLMD)
Revenue for the quarter came in at... Relmada Therapeutics (NASDAQ:RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83). For earnings history and earnings-related ...